US senator moves to limit Trump's war powers on Iran, as Mideast conflict escalates
Tim Kaine of Virginia has tried for years to wrest back Congress's authority to declare war from the White House.
During Trump's first term, in 2020, Kaine introduced a similar resolution to rein in Trump's ability to wage war against Iran. That measure passed both the Senate and House of Representatives, winning some Republican support, but did not garner enough votes to survive the Republican president's veto.
Kaine said his latest war powers resolution underscores that the US Constitution gives Congress, not the president, the sole power to declare war and requires that any hostility with Iran be explicitly authorised by a declaration of war or specific authorisation for the use of military force.
"It is not in our national security interest to get into a war with Iran unless that war is absolutely necessary to defend the United States. I am deeply concerned that the recent escalation of hostilities between Israel and Iran could quickly pull the United States into another endless conflict," Kaine said in a statement.
Under US law, war powers resolutions are privileged, meaning that the Senate will be required to promptly consider and vote on the matter.
Israel's military launched attacks on Iran on Friday with the stated aim of wiping out Iran's nuclear and ballistic missile programmes. Iran, which says its nuclear programme is for peaceful purposes, responded with missile attacks on Israel.
Both countries have kept up their attacks, killing and wounding civilians and raising concern among world leaders meeting in Canada this week that the biggest battle between the two old enemies could lead to a broader regional conflict.
Trump has lauded Israel's offensive while denying Iranian allegations that the US has taken part and warning Tehran not to widen its retaliation to include US targets.
Before leaving for the summit in Canada on Sunday, Trump was asked what he was doing to de-escalate the situation. "I hope there's going to be a deal. I think it's time for a deal," he told reporters. "Sometimes they have to fight it out."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNA
an hour ago
- CNA
Trump moves nuclear submarines after statements by former Russian president
WASHINGTON: US President Donald Trump said on Friday (Aug 1) he had ordered two nuclear submarines to be repositioned to the "appropriate regions" in response to recent threats from former Russian President Dmitry Medvedev. 'I have ordered two nuclear submarines to be positioned in the appropriate regions, just in case these foolish and inflammatory statements are more than just that,' Trump posted on social media. He described Medvedev's recent remarks as 'highly provocative' and warned that 'words are very important, and can often lead to unintended consequences. I hope this will not be one of those instances.' The move marks the latest escalation in rhetoric between the two leaders, who have traded barbs over Russia's ongoing war in Ukraine. On Tuesday, Trump gave Moscow a 10-day deadline to agree to a ceasefire or face new US tariffs on Russian oil and on countries that purchase it. Russia has not signaled any willingness to meet Trump's conditions and continues to advance its own demands for peace. Medvedev, currently deputy chairman of Russia's Security Council, responded by accusing Trump of playing a 'game of ultimatums' and reminded the US leader of Russia's legacy nuclear strike capabilities inherited from the Soviet Union. The Kremlin has not directly commented on Trump's latest move, but Medvedev's remarks were widely covered in Russian state media. Once seen as a more moderate figure, Medvedev has in recent years become one of Moscow's most vocal anti-Western hardliners, often issuing hawkish statements that Kremlin critics describe as reckless. However, some Western diplomats view Medvedev's rhetoric as a window into broader thinking within the Kremlin's senior policy circles.
International Business Times
2 hours ago
- International Business Times
Appeals Court Questions Trump's Use of Emergency Powers to Justify Tariffs
A US federal appeals court raised serious doubts about President Donald Trump's authority to impose broad tariffs under emergency powers. During a hearing in Washington, D.C., judges questioned whether the International Emergency Economic Powers Act (IEEPA) grants the president the legal right to impose tariffs on allied nations like Canada, China, and Mexico. Trump had used IEEPA to introduce what he called "reciprocal" tariffs in April and further increased them in February. The case now before the U.S. Court of Appeals for the Federal Circuit was brought by five small businesses and 12 Democratic-led states. They argue that Trump overstepped his powers and that only Congress has the constitutional right to set tariffs and taxes. Government lawyer Brett Shumate defended Trump's move, saying IEEPA gives the president broad authority in economic emergencies, including regulating imports. But Judge Jimmie Reyna responded, "IEEPA doesn't even mention tariffs." Several judges appeared skeptical throughout the 90-minute hearing, which concluded without a ruling date. The outcome of this case could have major implications. Trump, who made tariffs a key trade tool during his second term, claims they helped address unfair trade practices and boosted U.S. manufacturing. He cited the U.S. trade deficit and illegal fentanyl imports as justification. However, critics argue these reasons do not constitute an "extraordinary threat" under the law. Earlier this year, a lower court also ruled that IEEPA does not support tariffs based on long-term trade imbalances. The appeals court has allowed the tariffs to stay in place while legal challenges continue. With customs duties now generating over $100 billion in revenue this fiscal year, tariffs have become a significant funding source. Still, economists warn that they raise consumer prices and disrupt supply chains. The Trump administration argues that removing tariff power could harm trade negotiations, although recent deals with the EU, Japan, and others have moved forward. Trump has warned of further tariff hikes on countries not reaching new trade deals by August 1. The final decision in this case is likely to head to the U.S. Supreme Court if either side loses.
International Business Times
2 hours ago
- International Business Times
Trump Demands Drug Price Cuts in Letters to 17 Pharma Giants Summary
US President Donald Trump has sent letters to 17 major pharmaceutical companies demanding they cut prescription drug prices in the United States. The letters, released Thursday by the White House, outline his plan to match U.S. prices with those in other developed countries. President Donald Trump addessses the nation after U.S. bombed Iran's nuclear facilities X Trump recently signed an executive order requiring drugmakers to offer "most-favored-nation" pricing. This means companies must sell medications to U.S. patients at the lowest price they offer elsewhere. If drug companies do not comply, Trump warned the government could import cheaper alternatives or take other steps. Companies that received the letters include Pfizer, Eli Lilly, Johnson & Johnson, Merck, Sanofi, and AstraZeneca. Trump had previously criticized earlier proposals from the industry, saying they prioritized profits over patient care. He also demanded that drugmakers return any excess profits made by raising prices overseas to compensate American taxpayers. Shares of major pharmaceutical firms fell after the announcement. Pfizer, Eli Lilly, and Gilead each dropped by around 2%, while a broader index of drug stocks declined 3%. Trump also suggested a system where companies can sell drugs directly to patients, bypassing middlemen, but only if they agree to international pricing rules. The president gave drugmakers a deadline of September 29 to respond with binding commitments. Health experts are skeptical that companies will meet Trump's demands. Some analysts believe the proposals are unlikely to result in immediate price changes, describing them as more political pressure than enforceable policy. Still, several companies, including Pfizer and Novartis, said they are open to working with the administration. Pfizer confirmed its ongoing talks with Trump officials to improve access and affordability for U.S. patients. U.S. drug prices remain among the highest in the world, with patients often paying nearly three times more than those in other developed countries. Drugmakers argue that sharp price cuts could harm innovation, but Trump insists bold action is needed to protect Americans from high costs.
